Christopher Staley1, Byron P Vaughn2, Carolyn T Graiziger2, Michael J Sadowsky1, Alexander Khoruts3,4. 1. BioTechnology Institute, University of Minnesota, 140 Gortner Labs, 1479 Gortner Avenue, St Paul, MN 55108, USA. 2. Department of Medicine Division of Gastroenterology, University of Minnesota, 401 East River Parkway, Variety Club Research Center, 1st Floor - Suite 131, Minneapolis, MN, 55455, USA. 3. BioTechnology Institute, University of Minnesota, 140 Gortner Labs, 1479 Gortner Avenue, St Paul, MN 55108, USA khoru001@umn.edu. 4. Wallin Biomedical Sciences Building, Center for Immunology, University of Minnesota, 2101 6th St SE, Minneapolis, MN 55414, USA.
Abstract
BACKGROUND: Recipients of faecal microbiota transplantation (FMT) in treatment of recurrent Clostridium difficile infection (RCDI) remain at markedly increased risk of re-infection with C. difficile with new antibiotic provocations. Urinary tract infections (UTIs) are common indications for antibiotics in these patients, often resulting in C. difficile re-infection. METHODS: We present a case series of 19 patients treated with parenteral aminoglycosides for UTI following FMT for RCDI. A 3 day outpatient regimen of once-daily intramuscular administration of gentamicin was used to treat 18 consecutive FMT recipients with uncomplicated UTI. One other patient was treated for a complicated UTI with intravenous amikacin. Profiling of 16S rRNA genes was used to track changes in faecal microbial community structure during this regimen in three patients. RESULTS: The protocol was highly effective in treating UTI symptoms. None of the patients suffered a re-infection with C. difficile The faecal microbial communities remained undisturbed by treatment with intramuscular administration of gentamicin. CONCLUSIONS: Despite falling out of favour in recent years, aminoglycoside antibiotics given parenterally have the advantage of minimal penetration into the gut lumen. A brief (3 day) course of parenteral gentamicin was safe and effective in curing UTI in patients at high risk of C. difficile infection without perturbing their gut microbiota.
BACKGROUND: Recipients of faecal microbiota transplantation (FMT) in treatment of recurrent Clostridium difficileinfection (RCDI) remain at markedly increased risk of re-infection with C. difficile with new antibiotic provocations. Urinary tract infections (UTIs) are common indications for antibiotics in these patients, often resulting in C. difficile re-infection. METHODS: We present a case series of 19 patients treated with parenteral aminoglycosides for UTI following FMT for RCDI. A 3 day outpatient regimen of once-daily intramuscular administration of gentamicin was used to treat 18 consecutive FMT recipients with uncomplicated UTI. One other patient was treated for a complicated UTI with intravenous amikacin. Profiling of 16S rRNA genes was used to track changes in faecal microbial community structure during this regimen in three patients. RESULTS: The protocol was highly effective in treating UTI symptoms. None of the patients suffered a re-infection with C. difficile The faecal microbial communities remained undisturbed by treatment with intramuscular administration of gentamicin. CONCLUSIONS: Despite falling out of favour in recent years, aminoglycoside antibiotics given parenterally have the advantage of minimal penetration into the gut lumen. A brief (3 day) course of parenteral gentamicin was safe and effective in curing UTI in patients at high risk of C. difficileinfection without perturbing their gut microbiota.
Authors: Christopher Staley; Trevor J Gould; Ping Wang; Jane Phillips; James B Cotner; Michael J Sadowsky Journal: J Microbiol Methods Date: 2015-05-06 Impact factor: 2.363
Authors: Lawrence J Brandt; Olga C Aroniadis; Mark Mellow; Amy Kanatzar; Colleen Kelly; Tina Park; Neil Stollman; Faith Rohlke; Christina Surawicz Journal: Am J Gastroenterol Date: 2012-03-27 Impact factor: 10.864
Authors: Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller Journal: N Engl J Med Date: 2013-01-16 Impact factor: 91.245
Authors: Marcus J Claesson; Qiong Wang; Orla O'Sullivan; Rachel Greene-Diniz; James R Cole; R Paul Ross; Paul W O'Toole Journal: Nucleic Acids Res Date: 2010-09-29 Impact factor: 16.971
Authors: Alexa Weingarden; Antonio González; Yoshiki Vázquez-Baeza; Sophie Weiss; Gregory Humphry; Donna Berg-Lyons; Dan Knights; Tatsuya Unno; Aleh Bobr; Johnthomas Kang; Alexander Khoruts; Rob Knight; Michael J Sadowsky Journal: Microbiome Date: 2015-03-30 Impact factor: 14.650
Authors: Mathias W Pletz; Sebastian Weis; Christina Forstner; Florian Wagenlehner Journal: Med Klin Intensivmed Notfmed Date: 2018-03 Impact factor: 0.840
Authors: Erica N Parker; Brett N Cain; Behnoush Hajian; Rebecca J Ulrich; Emily J Geddes; Sulyman Barkho; Hyang Yeon Lee; John D Williams; Malik Raynor; Diana Caridha; Angela Zaino; Mrinal Shekhar; Kristen A Muñoz; Kara M Rzasa; Emily R Temple; Diana Hunt; Xiannu Jin; Chau Vuong; Kristina Pannone; Aya M Kelly; Michael P Mulligan; Katie K Lee; Gee W Lau; Deborah T Hung; Paul J Hergenrother Journal: ACS Cent Sci Date: 2022-08-10 Impact factor: 18.728
Authors: Danielle Barrios Steed; Tiffany Wang; Divyanshu Raheja; Alex D Waldman; Ahmed Babiker; Tanvi Dhere; Colleen S Kraft; Michael H Woodworth Journal: mSphere Date: 2020-10-14 Impact factor: 4.389